What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

被引:79
|
作者
Petrini, P [1 ]
机构
[1] Karolinska Hosp, Dept Paediat, S-17176 Stockholm, Sweden
关键词
haemophilia; prophylaxis; trough level;
D O I
10.1046/j.1365-2516.2001.00471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1-2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988-98 with severe haemophilia A or B needed a Port-a-Cath(R) for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0-4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 50 条
  • [21] Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden
    Carlsson, KS
    Höjgård, S
    Lethagen, S
    Lindgren, A
    Berntorp, E
    Lindgren, B
    HAEMOPHILIA, 2004, 10 (05) : 527 - 541
  • [22] Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A
    Fischer, K.
    Lewandowski, D.
    Janssen, M. P.
    HAEMOPHILIA, 2016, 22 (05) : E375 - E382
  • [23] Treatment of inhibitors in children with severe haemophilia B
    Baker, K.
    Efford, J.
    Henderson, L.
    Khair, K.
    Liesner, R.
    Mathias, N.
    HAEMOPHILIA, 2010, 16 : 69 - 69
  • [24] IMPROVED ARTHROPATHY SCORES AFTER USE OF EXTENDED HALF LIFE (EHL) PRODUCTS IN PROPHYLACTIC TREATMENT OF ADULT PATIENTS WITH SEVERE HAEMOPHILIA A AND B
    Kouramba, A.
    Thivaios, G.
    George, V.
    Elefterios, K.
    Zygogiannis, K.
    Katsarou, O.
    HAEMOPHILIA, 2020, 26 : 53 - 53
  • [25] Prophylactic factor substitution in severe haemophilia A Economic assessment in adult patients
    Berger, K.
    Schopohl, D.
    Eheberg, D.
    Oldenburg, J.
    Tiede, A.
    Schramm, W.
    HAMOSTASEOLOGIE, 2014, 34 (04): : 291 - 300
  • [26] Efficacy and safety of prophylactic treatment with Human-cl rhFVIII in previously treated patients with severe haemophilia A
    Lissitchkov, T.
    Hampton, K.
    Von Depka, M.
    Rangarajan, S.
    Hay, C.
    Tuddenham, E. D. G.
    Collins, P. W.
    Holstein, K.
    Huth-Kuehne, A.
    Pabinger, I.
    Bichler, J.
    Knaub, S.
    Oldenburg, J.
    HAEMOPHILIA, 2012, 18 (05) : 828 - 828
  • [27] Evaluation of prophylactic treatment of severe haemophilia a patients under 18 years of age: experience at a single centre
    Martorell, M.
    Altisent, C.
    Alvarez, E.
    Alonso, S.
    Parra, R.
    HAEMOPHILIA, 2014, 20 : 55 - 56
  • [28] Long-term outcome of individualized prophylactic treatment of children with severe haemophilia
    van den Berg, HM
    Fischer, K
    Mauser-Bunschoten, EP
    Beek, FJA
    Roosendaal, G
    van der Bom, JG
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) : 561 - 565
  • [29] Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies
    van den Berg, HM
    Fischer, K
    van der Bom, JG
    Roosendaal, G
    Mauser-Bunschoten, EP
    HAEMOPHILIA, 2002, 8 : 43 - 46
  • [30] What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers
    Lane, S.
    Arnold, E.
    Webert, K. E.
    Chan, A.
    Walker, I.
    Heddle, N. M.
    HAEMOPHILIA, 2013, 19 (04) : 503 - 510